Business context and reporting period
This is Gemini Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a filing by Disc Medicine, Inc., as indicated in the request metadata. Gemini was a clinical-stage biotechnology company developing treatments for age-related macular degeneration (AMD). It had no product revenue.
In January 2022, Gemini discontinued both Phase 2a trials of lead candidate GEM103. GEM307 remained preclinical. In February, the company announced a major restructuring and began evaluating strategic alternatives.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $9.8 million | $11.8 million |
| General and administrative expense | $5.4 million | $4.7 million |
| Total operating expenses | $15.2 million | $16.5 million |
| Net loss | $15.2 million | $19.0 million |
| Basic and diluted loss per share | $0.35 | $0.59 |
| Net cash used in operating activities | $16.3 million | $15.0 million |
At March 31, 2022, cash and cash equivalents were $119.1 million (plus $0.3 million restricted cash); total assets were $124.3 million, total liabilities $12.7 million, and stockholders’ equity $111.6 million. Term-loan principal outstanding was approximately $4.2 million, all classified as current; maturity was January 2023. The filing reports no product revenue, so a revenue margin is not applicable.
Material changes versus the prior comparable period
- Net loss narrowed by $3.8 million, principally reflecting lower R&D expense and the absence of the prior-year convertible-note discount accretion and conversion loss.
- R&D expense declined $2.0 million, primarily due to reduced GEM103 clinical activity, lab-space elimination, and lower R&D headcount.
- G&A expense increased $0.7 million, including severance and stock-based compensation.
- Operating cash use increased $1.3 million year over year. Cash and cash equivalents fell $17.6 million from December 31, 2021, including operating cash use and term-loan repayments.
Outlook, risks, and unusual items
Management said available cash was expected to fund planned operations for at least 12 months from the filing date, while cautioning that plans and cash needs could change, particularly depending on the strategic review. The company expected 2022 expenses to decline due to reduced clinical activity and restructuring. No timetable or definitive course of action had been set for the strategic alternatives review; there was no assurance of a transaction, favorable terms, increased stockholder value, or further cash distributions.
The February 2022 restructuring targeted up to 24 positions, approximately 80% of the then workforce, and was expected to be completed by the end of Q2 2022. Gemini recorded $1.7 million of related costs in Q1. Interim CEO Georges Gemayel succeeded Jason Meyenburg, who remained an advisor.
Risks include the halted GEM103 trials, the early stage of GEM307, lack of revenue and profitability, need for future capital if operations continue, uncertain strategic-review outcome, and clinical, regulatory, manufacturing, intellectual-property, and market risks. The company reported no material legal proceedings and no material changes to the risk factors in its 2021 Form 10-K. Management assessed disclosure controls as effective as of March 31, 2022.
Important facts for investors to verify
- Confirm the issuer identity: this filing is Gemini Therapeutics, Inc. (Nasdaq: GMTX), not Disc Medicine.
- Check subsequent filings and announcements for the strategic review’s outcome, any transaction, or changes to operating plans and cash runway.
- Verify completion and total costs of the workforce reduction, and any resulting obligations.
- Review subsequent cash use, term-loan repayment and maturity details, and whether additional financing was needed.
- Assess the status of GEM307 and whether any development plans changed after the GEM103 trial discontinuations.